Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A user experienced excessive hair shedding after taking 17 mg of Zinc gluconate daily for acne. They are seeking advice on similar experiences and solutions.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.

A 16-year-old noticed hair thinning on the crown and sides of the head, with minimal temple thinning. After using Minoxidil for 6 months, some areas improved, but the crown worsened, and they seek advice on the irregular hair loss and treatment options.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

A 16-year-old is experiencing thinning hair at the front and shedding during showers. He is concerned about potential early baldness and is considering seeing a doctor and taking multivitamins.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

A user's experience with aggressive hair loss from age 18-22, and possible treatments to combat this such as Dut, oral minoxidil, and finasteride.

GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.

A 17-year-old is experiencing rapid hair loss over two weeks and is advised that treatments like minoxidil and finasteride can help. It's noted that lighting and angles can affect the appearance of hair loss, and a guide is recommended for further advice.

A 17-year-old started using 1mg oral finasteride in April 2025 and increased oral minoxidil from 1.25mg to 2.5mg by December 2025. Users discuss progress, initial shedding, and suggest checking vitamin and mineral levels.

A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation is about dealing with hair loss and exploring treatments like HRT, Minoxidil, and micro-needling. The user is considering wigs and possibly a hair transplant while expressing feelings of self-doubt and seeking support.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user reports success in treating hair loss using finasteride, minoxidil, Nizoral, vitamin D3, biotin, and dermarolling. They noticed improved hair growth, especially after addressing a severe vitamin D deficiency and changing their minoxidil regimen.

The user experienced hair regrowth using topical minoxidil and finasteride, and later added oral finasteride for maintenance. They reported no side effects and found a specific shampoo helpful for scalp issues.